Rash News and Research

RSS

Ledipasvir/sofosbuvir combination approved for hepatitis C treatment does not require antiviral drug

The drug approved to treat patients infected with the hepatitis C virus needs no help from other antivirals, according to a study released online this week in the journal Hepatology.

2 Jul 2015

Penn State dermatologist provides tips for treating poison ivy rash

Dr. David Adams, a dermatologist at Penn State Hershey, doesn't buy recent news reports that poison ivy has become stronger and more prevalent lately.

2 Jul 2015

Cosmederm Bioscience expands TriCalm's line of anti-itch products to further benefit sufferers of itch

Cosmederm Bioscience, Inc. today announced the expansion of its itch-relief product line, TriCalm, with the new TriCalm Clinical Repair Cream and TriCalm Extra Strength Spray. Following the success of the company's initial product, TriCalm Hydrogel, these two new offerings strategically expand the brand's line of steroid-free, anti-itch products to further benefit sufferers of itch.

29 Jun 2015

Basilea announces UK launch of broad-spectrum Cephalosporin Zevtera for first-line treatment of pneumonia

Basilea Pharmaceutica AG today announces the UK launch of its broad-spectrum Cephalosporin Zevtera (Ceftobiprole medocaril) for the first-line treatment of serious bacterial pneumonia.

25 Jun 2015

FDA provides safety update about Essure Birth Control Implant

The FDA first announced their intention to provide a safety update about Essure late yesterday evening. Today's much anticipated report comes on the heals of a private citizen petition that raised serious concerns about the Essure Birth Control Implant and resulted in the launch of an FDA investigation into the birth control device.

25 Jun 2015

Vanderbilt expert offers tips for preventing and treating poison ivy

It's the time of year when backyards attract children, trails beckon hikers, and poison ivy attacks the unwary. This itch-causing plant pest, along with its cohorts poison oak and poison sumac, cause more common allergic reactions than any other source, said Renee Miller, R.N., a certified specialist in poison information at the Tennessee Poison Center at Vanderbilt University Medical Center.

4 Jun 2015

Elusys’ Anthim BLA to treat inhalational anthrax accepted for review by the FDA

Elusys Therapeutics, Inc. today announced the U.S. Food and Drug Administration has accepted for filing and review its Biologics License Application for Anthim® (obiltoxaximab) for the treatment and prevention of inhalational anthrax, a top bioterror threat which was submitted on March 20, 2015. Anthim is a candidate for future acquisition into the Strategic National Stockpile, the U.S. government's repository of critical medical supplies for biowarfare preparedness.

2 Jun 2015

Boehringer Ingelheim presents afatinib LUX-Lung 8 trial data at ASCO 2015

2 Jun 2015

AstraZeneca announces efficacy and safety data for AZD9291 in first-line treatment of EGFRm advanced NSCLC

AstraZeneca today announced preliminary efficacy and safety data for AZD9291 in the first-line treatment of epidermal growth factor receptor mutation positive (EGFRm) advanced non-small cell lung cancer (NSCLC).

2 Jun 2015

Combination of Tafinlar and Mekinist drugs improves outcomes in patients with metastatic melanoma

Novartis today announced data from the Phase III COMBI-d study showing a significant survival benefit for patients with BRAF V600E/K mutation-positive metastatic melanoma when treated with the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) compared to Tafinlar monotherapy alone.

2 Jun 2015

Combination of cobimetinib and vemurafenib can halt progression of metastatic melanoma for one year

Data from the pivotal coBRIM Phase III study, presented by Lead Investigator Dr James Larkin today at the American Society of Clinical Oncology (ASCO) annual meeting, demonstrate that Roche’s investigational MEK inhibitor cobimetinib, used in combination with BRAF inhibitor vemurafenib, typically offers people with previously untreated advanced metastatic melanoma (BRAFV600 mutation-positive unresectable or metastatic) one full year (median 12.3 months) without their disease worsening.

2 Jun 2015

Pennsylvania physicians urge residents to take precautions against bug bites, bee stings

For many people, bug bites and bee stings aren't a big deal beyond a small irritation. But for some, it could mean the start of a painful - possibly long-term or even deadly - experience.

1 Jun 2015

Boehringer announces LUX-Lung 8 data that compares efficacy of afatinib, erlotinib in patients with advanced SCC

Boehringer Ingelheim today announced overall survival (OS) results from the LUX-Lung 8 trial (NCT01523587) that directly compared the efficacy and safety of two EGFR-directed treatments, afatinib and erlotinib, in patients with advanced squamous cell carcinoma (SCC) of the lung, progressing after treatment with first-line chemotherapy. Treatment with afatinib significantly reduced the risk of death by 19%, extending the survival of patients to a median of 7.9 months compared to 6.8 months on erlotinib.

1 Jun 2015

Asterias reports positive data from AST-VAC1 Phase 2 trial for intermediate, high risk AML

Asterias Biotherapeutics, Inc., a biotechnology company focused on the emerging field of regenerative medicine, today announced positive, new, long-term follow-up data from a Phase 2 clinical trial of AST-VAC1 in patients with intermediate and high risk acute myelogenous leukemia (AML).

1 Jun 2015

Combination of Mekinist and Tafinlar drugs improves outcome in patients with metastatic melanoma

1 Jun 2015

CHEMOSAT treatment of UM patients with hepatic metastases highlighted at ASCO 2015

Delcath Systems, Inc., a specialty pharmaceutical and medical device company focused on oncology with an emphasis on the treatment of primary and metastatic liver cancers, announces that results of a large, European single-center experience of the treatment of uveal melanoma patients with hepatic metastases with the Delcath Hepatic CHEMOSAT® Delivery System, were highlighted in an on-line abstract at the American Society of Clinical Oncology Annual Meeting 2015.

1 Jun 2015

Pembrolizumab (Keytruda) effective in patients with recurrent or metastatic head and neck cancer

Immunotherapy with the anti-PD-1 antibody pembrolizumab (Keytruda) was effective in one out of four patients with recurrent or metastatic head and neck cancer, according to results presented at the 2015 meeting of the American Society for Clinical Oncology.

30 May 2015

Monoclonal antibody nivolumab improves survival rates of melanoma patients

The monoclonal antibody nivolumab has shown promise as a therapeutic agent, particularly by improving the survival rates of melanoma patients. Jeffrey S. Weber, M.D., Ph.D., director of the Donald A. Adam Comprehensive Melanoma Research Center at Moffitt Cancer Center will be presenting data from a retrospective analysis of the safety of nivolumab in 4 ongoing phase I-III studies in melanoma patients at the 2015 American Society of Clinical Oncology Annual Meeting in Chicago.

29 May 2015

Impulsive behavior could put you at risk for binge eating

Do you get impulsive when you're upset? If so, this could be putting you at risk for binge eating. According to Kelly Klump, professor of psychology at Michigan State University and senior author, the more impulsive you are, the more likely it is you'll binge eat when experiencing negative feelings.

29 May 2015

Novel survey shows high rates of tattoo-related infection, itching and swelling in New Yorkers

In what they believe to be the first survey of its kind in the United States, researchers at NYU Langone Medical Center have found that as many as 6 percent of adult New Yorkers who get "inked" — in other words, those who get a tattoo — have experienced some form of tattoo-related rash, severe itching or swelling that lasted longer than four months and, in some cases, for many years.

28 May 2015

Rash News and Research

Ledipasvir/sofosbuvir combination approved for hepatitis C treatment does not require antiviral drug

Penn State dermatologist provides tips for treating poison ivy rash

Cosmederm Bioscience expands TriCalm's line of anti-itch products to further benefit sufferers of itch

Basilea announces UK launch of broad-spectrum Cephalosporin Zevtera for first-line treatment of pneumonia

FDA provides safety update about Essure Birth Control Implant

Vanderbilt expert offers tips for preventing and treating poison ivy

Elusys’ Anthim BLA to treat inhalational anthrax accepted for review by the FDA

Boehringer Ingelheim presents afatinib LUX-Lung 8 trial data at ASCO 2015

AstraZeneca announces efficacy and safety data for AZD9291 in first-line treatment of EGFRm advanced NSCLC

Combination of Tafinlar and Mekinist drugs improves outcomes in patients with metastatic melanoma

Combination of cobimetinib and vemurafenib can halt progression of metastatic melanoma for one year

Pennsylvania physicians urge residents to take precautions against bug bites, bee stings

Boehringer announces LUX-Lung 8 data that compares efficacy of afatinib, erlotinib in patients with advanced SCC

Asterias reports positive data from AST-VAC1 Phase 2 trial for intermediate, high risk AML

Combination of Mekinist and Tafinlar drugs improves outcome in patients with metastatic melanoma

CHEMOSAT treatment of UM patients with hepatic metastases highlighted at ASCO 2015

Pembrolizumab (Keytruda) effective in patients with recurrent or metastatic head and neck cancer

Monoclonal antibody nivolumab improves survival rates of melanoma patients

Impulsive behavior could put you at risk for binge eating

Novel survey shows high rates of tattoo-related infection, itching and swelling in New Yorkers

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News